ClickCease

Product Defect Case Series

Allison v. Merck & Co., 110 Nev. 762, 878 P.2d 948 (1994).

Product:

Injury:

Mechanism of Injury:

Nature of Defect:

Jury Verdict:

Issue on appeal:

Product Defect Law Categories:

Full Case Text:  Allison v. Merck & Co., 110 Nev. 762, 878 P.2d 948 (1994).

Result:

Case Quotes:

To establish liability under a strict tort liability theory, Thomas must establish that his injury “was caused by a defect in the product, and that such defect existed when the product left the hands of the defendant.” Shoshone Coca–Cola Co. v. Dolinski, 82 Nev. 439, 443, 420 P.2d 855, 858 (1966).

Allison v. Merck & Co., 110 Nev. 762, 767, 878 P.2d 948, 952 (1994).

 


We have already considered the meaning of the word “defect” in connection with strict products liability. In Ginnis v. Mapes Hotel Corp., we adopted a definition of “defect” that is still useful and applicable to the case at hand: “ ‘Although the definitions of the term “defect” in the context of products liability law use varying language, all of them rest upon the common premise that those products are defective which are dangerous because they fail to perform in the manner reasonably to be expected in light of their nature and intended function.’ ” 86 Nev. 408, 413, 470 P.2d 135, 138 (1970) (quoting Dunham v. Vaughn & Bushnell Mfg. Co., 42 Ill.2d 339, 247 N.E.2d 401, 403 (1969)).

Allison v. Merck & Co., 110 Nev. 762, 767, 878 P.2d 948, 952 (1994).

 


If Thomas can establish that the vaccine caused him to suffer permanent brain damage, then surely the vaccine failed to perform in the manner reasonably to be expected “in light of [its] nature and intended function.” The nature and intended function of this vaccine, of course, is to create an immunity to measles, mumps and rubella without attendant blindness, deafness, mental retardation and permanent brain damage.4

Allison v. Merck & Co., 110 Nev. 762, 767, 878 P.2d 948, 952 (1994).

 


Under the law of strict liability in this state, responsibility for injuries caused by defective products is properly fixed wherever it will most effectively reduce the hazards to life and health inherent in defective products that reach the market.

Allison v. Merck & Co., 110 Nev. 762, 767-68, 878 P.2d 948, 952 (1994).

 


Although manufacturers are not insurers of their products, where injury is caused by a defective product, responsibility is placed upon the manufacturer and the distributor of the defective product rather than on the injured consumer. See Stackiewicz v. Nissan Motor Corp., 100 Nev. 443, 448, 686 P.2d 925, 928 (1984); see also Nat'l Union Fire Ins. v. Pratt and Whitney, 107 Nev. 535, 815 P.2d 601 (1991).

Allison v. Merck & Co., 110 Nev. 762, 768, 878 P.2d 948, 952 (1994).

 


In Stackiewicz, we allowed a strict liability case to go to the jury on the plaintiff's claim of an idiopathic steering defect in an automobile which the plaintiff claimed was the cause of her injuries. We said in Stackiewicz that when “ ‘machinery “malfunctions,” it obviously lacks fitness regardless of the cause of the malfunction.’ ” Id. at 448–49, 686 P.2d at 928 (quoting Lindsay v. McDonnell Douglas Aircraft Corp., 460 F.2d 631, 639 (8th Cir.1972)).

Allison v. Merck & Co., 110 Nev. 762, 768, 878 P.2d 948, 952 (1994).

 


In the case before us, plaintiffs are claiming in effect that the vaccine “malfunctioned”; and, if we are to follow Stackiewicz, then a vaccine which causes permanent brain damage “obviously lacks fitness regardless of the cause of the malfunction.”5 If the vaccine is found by a factfinder to have caused Thomas to develop the disabling encephalitis, then Merck's “ ‘ “sin” is the lack of fitness as evidenced by the malfunction itself rather than some specific dereliction by the manufacturer.’ ” Id. 100 Nev. at 449, 686 P.2d at 928 (quoting Lindsay, 460 F.2d at 639).

Allison v. Merck & Co., 110 Nev. 762, 768, 878 P.2d 948, 952-53 (1994).

 


Unless we are going to abandon long-standing public policy grounds for holding manufacturers and distributors of defective products responsible for injuries caused by manufactured products that prove to be defective, Thomas must be given an opportunity to prove that a malfunctioning vaccine caused his injuries, just as we allowed Ms. Stackiewicz to try to prove that her injuries were caused by a defective steering mechanism.

Allison v. Merck & Co., 110 Nev. 762, 769, 878 P.2d 948, 953 (1994).

 


The public policy considerations that support holding the defendants liable in this case (if plaintiffs can prove that the vaccine caused his injuries) were put well by Professor Prosser in the noted law review article, “The Fall of the Citadel”:

 

The public interest in human safety requires the maximum possible protection for the user of the product, and those best able to afford it are the suppliers of the chattel. By placing their goods upon the market, the suppliers represent to the public that they are suitable and safe for use; and by packaging, advertising and otherwise, they do everything they can to induce that belief....

50 Minn.L.Rev. 791, 799 (1966). This concept of “public interest” is the guiding principle of our present opinion.

 

Allison v. Merck & Co., 110 Nev. 762, 769, 878 P.2d 948, 953 (1994).

 


Merck claims that it is free from strict manufacturer's liability by virtue of the dictum stated in comment k to section 402A of the Restatement (Second) of Torts.7 This comment suggests that a drug manufacturer should not be held liable for “the unfortunate consequences attending” the use of its drugs if: (1) the manufacturer supplies “the public with an apparently useful and desirable product, attended by a known but apparently reasonable risk,” (2) the drug is “properly prepared and marketed,” and (3) “proper warning is given.”

It is not easy to divine just why the framers of the comment thought that a drug manufacturer should be excused in cases in which it manufactured a drug that was “known” to be dangerous. The whole idea behind strict tort liability is that the manufacturer, not the consumer, should bear the responsibility for injuries, even when the product is ostensibly properly prepared and marketed and when the plaintiff is not in a position to prove the origin of the defect.8 See Stackiewicz, 100 Nev. at 443, 686 P.2d at 925.

 

Allison v. Merck & Co., 110 Nev. 762, 769-70, 878 P.2d 948, 953-54 (1994).

 


What the question in this case really gets down to is whether an exception should be made in a case in which a drug manufacturer injures a consumer with a drug that it knows is dangerous, but not too (“unreasonably”) dangerous. That is to say, should a drug manufacturer be allowed to profit with impunity from the distribution of a drug that it knows is capable of resulting in physical injury, so long as the drug can somehow be certified as not being unreasonably dangerous? We answer that question in the negative and say that a drug manufacturer should, under the strict liability jurisprudence of this state, be held liable in tort even when the drug is “properly prepared and marketed” (that is to say, non-negligently ) and even when the known danger inherent in the drug may be what the comment calls “reasonable.”

Allison v. Merck & Co., 110 Nev. 762, 770-71, 878 P.2d 948, 954 (1994).

 


The apparent rationale of comment k in relieving drug manufacturers from liability is that where the manufacturer is free from fault, that is to say it produces a product that is unsafe because of a claim by the manufacturer that it is “incapable of being made safe,” the manufacturer should not be responsible for injuries resulting from use of the drug. The comment itself gives as an example of such an “unavoidably unsafe” drug the Pasteur treatment of rabies “which not uncommonly leads to very serious and damaging consequences when it is injected.” We would note, however, that the reason why serious and damaging consequences of the Pasteur rabies treatment do not result in tort liability is not because of the “unreasonably dangerous” doctrine proposed by comment k, but, rather, because the victim chooses to be injected with a drug having known “damaging consequences” rather than to die from rabies. It is the voluntary choice to take the antirabies serum that eliminates tort liability and not the serum's being said to be unavoidably or reasonably dangerous. There is no need to make an exception to the rules of strict liability such as that suggested by comment k in the rabies example because the rabies victim waives tort claims by accepting what the victim knows to be the necessary risk involved in the treatment.9

Allison v. Merck & Co., 110 Nev. 762, 771, 878 P.2d 948, 954 (1994).

 


Speaking of “unavoidable” danger or fault-free infliction of harm, or speaking of reasonable (and therefore acceptable) risk of harm, is very much alien to strict liability theory and should have no place in the Restatement provisions relating to strict  liability. Mixing concepts of fault-free (“unavoidable”) manufacture and “reasonable risk” into the context of non-negligent, strict liability is entirely inconsistent with our products liability cases and with the law established in this state for almost thirty years. The well-accepted principle supporting our products liability cases is expressed in comment c of section 402 A of the Restatement:


[P]ublic policy demands that the burden of accidental injuries caused by products intended for consumption be placed upon those who market them, and be treated as a cost of production against which liability insurance can be obtained; and that the consumer of such products is entitled to the maximum of protection at the hands of someone, and the proper persons to afford it are those who market the products.

Allison v. Merck & Co., 110 Nev. 762, 771-72, 878 P.2d 948, 955 (1994).

 


It could not be said any more clearly than this. Merck, not Thomas Allison, must, if the Merck product did in fact cause Thomas' overwhelming misfortune, bear the “burden of the accidental [intended] injuries caused by products intended for consumption.” Restatement (Second) of Torts, § 402 A, cmt. c (1965).

Allison v. Merck & Co., 110 Nev. 762, 772, 878 P.2d 948, 955 (1994).

 


Although, on policy grounds, Merck might talk some legislative body into immunizing it from liability, it would be certainly inappropriate for the court to make such a radical change in our well-established products liability law. Further, one would think that if a legislature were going to give such special benefits to drug manufacturers, most certainly the resultant legislation, to be just, would have to afford some kind of compensation or relief to the victims of “unavoidably unsafe” drugs. If, for example, a legislature provided that automobile manufacturers would be held to a standard of strict liability for manufacturing defects, even if injuries caused by a given defect are statistically infrequent and perhaps “unavoidable,” and at the same time immunized drug manufacturers from liability for injuries caused by their vaccines, the legislature would, as mentioned, very probably and properly include in such discriminatory legislation some kind of no-fault victim compensation plan to set off the advantage given to drug manufacturers over other kinds of manufacturers.10

Allison v. Merck & Co., 110 Nev. 762, 772-73, 878 P.2d 948, 955 (1994).

Clear Counsel Law group

Contact Info

1671 W Horizon Ridge Pkwy Suite 200,
Henderson, NV 89012

+1 702 522 0696
info@clearcounsel.com

Daily: 9:00 am - 5:00 pm
Saturday & Sunday: By Appointment Only

Copyright 2019 Clear Counsel Law Group® | Nav Map

Nothing on this site is legal advice.